These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35530142)

  • 1. Artificial tumor microenvironment regulated by first hemorrhage for enhanced tumor targeting and then occlusion for synergistic bioactivation of hypoxia-sensitive platesomes.
    Tao W; Zhao D; Li G; Li L; Li S; Ye H; Tian C; Lu Y; Li S; Sun Y; He Z; Sun J
    Acta Pharm Sin B; 2022 Mar; 12(3):1487-1499. PubMed ID: 35530142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
    Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
    Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature.
    Chen J; Jiang Z; Xu W; Sun T; Zhuang X; Ding J; Chen X
    Nano Lett; 2020 Aug; 20(8):6191-6198. PubMed ID: 32697585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Light-triggered dual-modality drug release of self-assembled prodrug-nanoparticles for synergistic photodynamic and hypoxia-activated therapy.
    Zhao D; Tao W; Li S; Li L; Sun Y; Li G; Wang G; Wang Y; Lin B; Luo C; Wang Y; Cheng M; He Z; Sun J
    Nanoscale Horiz; 2020 May; 5(5):886-894. PubMed ID: 32219262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development and use of vascular targeted therapy in ovarian cancer.
    Chase DM; Chaplin DJ; Monk BJ
    Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic PEG-coated ROS-sensitive prodrug nanoassemblies for core-shell synergistic chemo-photodynamic therapy.
    Sun B; Chen Y; Yu H; Wang C; Zhang X; Zhao H; Chen Q; He Z; Luo C; Sun J
    Acta Biomater; 2019 Jul; 92():219-228. PubMed ID: 31078764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining combretastatin A4 phosphate with ginsenoside Rd synergistically inhibited hepatocellular carcinoma by reducing HIF-1α via PI3K/AKT/mTOR signalling pathway.
    Yang X; Gao M; Miao M; Jiang C; Zhang D; Yin Z; Ni Y; Chen J; Zhang J
    J Pharm Pharmacol; 2021 Mar; 73(2):263-271. PubMed ID: 33793802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.
    Liu Z; Zhang Y; Shen N; Sun J; Tang Z; Chen X
    Adv Drug Deliv Rev; 2022 Apr; 183():114138. PubMed ID: 35143895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
    Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
    Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation.
    Liu Y; Wang S; Zhao X; Feng Y; Bormans G; Swinnen J; Oyen R; Huang G; Ni Y; Li Y
    Diagnostics (Basel); 2020 Jan; 10(2):. PubMed ID: 32024029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Biomimetic Platesomes for pH-Responsive Drug Delivery and Enhanced Antitumor Activity.
    Liu G; Zhao X; Zhang Y; Xu J; Xu J; Li Y; Min H; Shi J; Zhao Y; Wei J; Wang J; Nie G
    Adv Mater; 2019 Aug; 31(32):e1900795. PubMed ID: 31222856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
    Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
    Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.
    Dey S; Kumari S; Kalainayakan SP; Campbell J; Ghosh P; Zhou H; FitzGerald KE; Li M; Mason RP; Zhang L; Liu L
    Oncotarget; 2018 Jan; 9(3):4090-4101. PubMed ID: 29423106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROS-sensitive biomimetic nanocarriers modulate tumor hypoxia for synergistic photodynamic chemotherapy.
    Liu H; Jiang W; Wang Q; Hang L; Wang Y; Wang Y
    Biomater Sci; 2019 Aug; 7(9):3706-3716. PubMed ID: 31187794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photosensitizer-driven nanoassemblies of homodimeric prodrug for self-enhancing activation and synergistic chemo-photodynamic therapy.
    Zhang S; Wang Z; Kong Z; Wang Y; Zhang X; Sun B; Zhang H; Kan Q; He Z; Luo C; Sun J
    Theranostics; 2021; 11(12):6019-6032. PubMed ID: 33897896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monensin Enhanced Generation of Extracellular Vesicles as Transfersomes for Promoting Tumor Penetration of Pyropheophorbide-a from Fusogenic Liposome.
    He Y; Wang K; Lu Y; Sun B; Sun J; Liang W
    Nano Lett; 2022 Feb; 22(3):1415-1424. PubMed ID: 35072479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supramolecular micelles as multifunctional theranostic agents for synergistic photodynamic therapy and hypoxia-activated chemotherapy.
    Huang X; Chen T; Mu N; Lam HW; Sun C; Yue L; Cheng Q; Gao C; Yuan Z; Wang R
    Acta Biomater; 2021 Sep; 131():483-492. PubMed ID: 34265471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate.
    Holmes T; Brown AW; Suggitt M; Shaw LA; Simpson L; Harrity JPA; Tozer GM; Kanthou C
    Sci Rep; 2020 Jun; 10(1):9926. PubMed ID: 32555222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
    Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
    World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.